

To the Press:

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

17 October 2012

Exiqon and Takara Bio Inc. partner on the distribution of miRCURY LNA™ products in Asia.

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced that Takara Bio Inc. will take over the distribution of miRCURY LNA™ products in Asia.

Takara Bio Inc. will market Exiqon's life sciences products in Japan, China, Hong Kong, South Korea and India.

Takara Bio Inc. is a leading provider and distributor of life science research products in Asia.

"We are pleased to announce that Takara Bio will distribute Exiqon's products in the important growth markets of India and East Asia", said Senior Vice President Sales & Marketing Exiqon, Henrik M. Pfundheller and added: "The interest for microRNA research and our miRCURY LNA™ product lines continues to grow rapidly throughout the world, and Asia is an important growth market where we expect customers will benefit from our combined efforts with Takara Bio to meet customer demand for high quality research products".

Takara Bio Inc. will initiate the distribution of Exiqon's products in January 2013 but will launch research services using Exiqon's products in December 2012.

Takara Bio Inc. joins Exiqon's network of distributors covering Central and Southern Europe, the Middle East, Brazil, Asia, Australia and New Zealand.

Additional information

Henrik M. Pfundheller, SVP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells and bodyfluids. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to target new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.